Jul 16, 2024
Press releases
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Jul 3, 2024
Press releases
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
Jul 1, 2024
Presentations
The Big Biz Show Interview with Evaxion's CEO Christian Kanstrup
In this interview, Bob "Sully" Sullivan and Mike Costa from the Big Biz Show interview our CEO, Christian Kanstrup, about Evaxion's Innovative AI-Immnuology™ platform, personalized cancer vaccines, and market projections.
Jun 26, 2024
Press releases
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
Jun 17, 2024
Press releases
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
Jun 3, 2024
Press releases
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
Jun 3, 2024
Press releases
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
Evaxion reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company’s AI-Immunology™ designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.
May 29, 2024
Publications
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX01) in patients with metastatic melanoma
Publication: Journal for ImmunoTherapy of Cancer
Authors: Sofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri, Arianna Draghi , Kalijn Bol , Mohammad Kadivar, Marie Christine Wulff Westergaard, Joachim Stoltenborg Granhøj, Annie Borch, Nadia Viborg Petersen, Nikolas Thuesen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Rebecca Bach Dohn, Christina Westmose Yde, Nis Noergaard, Torben Lorentzen, Anders Bundgaard Soerensen, Daniela Kleine-Kohlbrecher, Anders Jespersen, Dennis Christensen, Jens Kringelum, Marco Donia, Sine Reker Hadrup, nge Marie Svane
May 28, 2024
Press releases
Evaxion Announces Business Update and First Quarter 2024 Financial Results
Evaxion provides business update and announces first quarter 2024 financial results.
May 23, 2024
Press releases
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
Evaxion announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study. The study assesses the personalized cancer vaccine EVX-01 in combination with anti-PD1 therapy in patients with advanced melanoma. The conference will take place in Chicago, IL, from May 31 – June 4, 2024.
May 10, 2024
Press releases
Evaxion Receives Nasdaq Notification
Evaxion announces that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders’ equity requirement.
Apr 24, 2024
Publications
Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens
Publication: Frontiers in Immunology
Authors: Michail Angelos Pavlidis, Nadia Viborg, Mads Lausen, Birgitte Rønø and Daniela Kleine-Kohlbrecher
Evaxion Media kit
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.